North America Is Dominating Next-Generation Antibody Therapeutics Industry

The next-generation antibody therapeutics market is projected to reach USD 15,308.6 million by 2030, advancing at a CAGR of 11.8% during 2021–2030.

The surging investments in the healthcare sector is set to boost the market. This is due to the high success rate of antibodies in the treatment of various chronic disease including autoimmune disease and cancer. Additionally, antibody–drug conjugates (ADCs) are being developed to address the rise in the incidence of chronic diseases. These advancements, along with the government grants, motivate the key players to increase their research and development activities, which would fuel the growth once the candidate receives the marketing approval.

It has been proven that antibodies are extremely useful for the management of numerous neurodegenerative disorders, as they can be directly administered into the brain, which is only possible with other modern medications.

The oncology category is expected to lead the market, advancing with the higher CAGR, of approximately 13%, in the forecast period. This is mainly because of the surge in the incidence of breast cancer, colorectal cancer, prostate cancer, brain cancer, and lung cancer, which can be treated with next-generation antibodies. Hence, the availability of next-generation antibody therapeutics, such as Kadcyla, ADCETRIS, and Poteligeo, for the treatment of cancer patients drives the domain revenue.

Based on region, North America leads the market, which can be attributed to the surge in the investment in research and development by both government and non-government organizations. In addition, the rising prevalence of chronic diseases in the region is driving the market growth.

The Asia-Pacific region is projected to advance with the highest CAGR, approximately 13%. This is because of the rising number of strategic partnerships amongst the prominent players in the region. The biggest reason, however, is the increasing incidence of cancer in regional countries and the rising need for advanced treatments for the same.